These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 16433588)
1. What are we looking for in new antibacterials and how do we design it? Barrett JF; Motyl M Expert Opin Investig Drugs; 2006 Feb; 15(2):85-8. PubMed ID: 16433588 [TBL] [Abstract][Full Text] [Related]
2. Recent developments in antibacterial drug discovery: microbe-derived natural products--from collection to the clinic. Leeds JA; Schmitt EK; Krastel P Expert Opin Investig Drugs; 2006 Mar; 15(3):211-26. PubMed ID: 16503759 [TBL] [Abstract][Full Text] [Related]
3. The future challenges facing the development of new antimicrobial drugs. Coates A; Hu Y; Bax R; Page C Nat Rev Drug Discov; 2002 Nov; 1(11):895-910. PubMed ID: 12415249 [TBL] [Abstract][Full Text] [Related]
4. New advances in antibiotic development and discovery. Alekshun MN Expert Opin Investig Drugs; 2005 Feb; 14(2):117-34. PubMed ID: 15757391 [TBL] [Abstract][Full Text] [Related]
5. [Looking for the new preparations for antibacterial therapy. I. New antibiotics and chemotherapeutics on the market]. Karpiuk I; Tyski S Przegl Epidemiol; 2012; 66(4):567-73. PubMed ID: 23484382 [TBL] [Abstract][Full Text] [Related]
6. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials. Karpiuk I; Tyski S Przegl Epidemiol; 2015; 69(4):723-9, 865-70. PubMed ID: 27139351 [TBL] [Abstract][Full Text] [Related]
7. Investigational new drugs for the treatment of resistant pneumococcal infections. Hoffman-Roberts HL; C Babcock E; Mitropoulos IF Expert Opin Investig Drugs; 2005 Aug; 14(8):973-95. PubMed ID: 16050791 [TBL] [Abstract][Full Text] [Related]
10. Antibiotics: where did we go wrong? Overbye KM; Barrett JF Drug Discov Today; 2005 Jan; 10(1):45-52. PubMed ID: 15676298 [TBL] [Abstract][Full Text] [Related]
11. Novel target sites in bacteria for overcoming antibiotic resistance. Black MT; Hodgson J Adv Drug Deliv Rev; 2005 Jul; 57(10):1528-38. PubMed ID: 15949866 [TBL] [Abstract][Full Text] [Related]
12. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. White AR; J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625 [TBL] [Abstract][Full Text] [Related]
13. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Karpiuk I; Tyski S Przegl Epidemiol; 2013; 67(3):455-60, 557-61. PubMed ID: 24340560 [TBL] [Abstract][Full Text] [Related]
14. Interscience Conference on Antimicrobial Agents and Chemotherapy--47th Annual Meeting. New antimicrobial agents: Part 1. 17-20 September 2007, Chicago, IL, USA. Din S IDrugs; 2007 Nov; 10(11):751-4. PubMed ID: 17968749 [No Abstract] [Full Text] [Related]
15. Antimicrobial resistance diagnostics: time to call in the young? Syed SN; Ducrotoy MJ; Bachmann TT Lancet Infect Dis; 2016 May; 16(5):519-521. PubMed ID: 27599645 [No Abstract] [Full Text] [Related]
16. Anadys Pharmaceuticals, Inc. Basbaum A Pharmacogenomics; 2003 Jul; 4(4):511-8. PubMed ID: 12831329 [TBL] [Abstract][Full Text] [Related]
17. Synthetic approaches to the 2003 new drugs. Liu KK; Li J; Sakya S Mini Rev Med Chem; 2004 Dec; 4(10):1105-25. PubMed ID: 15579116 [TBL] [Abstract][Full Text] [Related]
18. Antibacterial discovery and development--the failure of success? Fernandes P Nat Biotechnol; 2006 Dec; 24(12):1497-503. PubMed ID: 17160049 [TBL] [Abstract][Full Text] [Related]
19. The erosion of research integrity: the need for culture change. Ellis LM Lancet Oncol; 2015 Jul; 16(7):752-4. PubMed ID: 26149871 [No Abstract] [Full Text] [Related]
20. Pharmacogenomics in anticoagulant drug development. Iqbal O Pharmacogenomics; 2002 Nov; 3(6):823-8. PubMed ID: 12437483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]